Impact of monocytic differentiation on acute myeloid leukemia patients treated with venetoclax and hypomethylating agents.

ABSTRACT:

Introduction

Although the combination of venetoclax (VEN) and hypomethylating agents (HMAs) results in impressive efficacy in acute myeloid leukemia (AML), there is still a subset of patients who are refractory. We investigated the outcomes of AML patients with monocytic differentiation who were treated with frontline VEN/HMA.

Methods

A total of 155 patients with newly diagnosed AML treated with frontline VEN/HMA were enrolled in the study. Monocyte-like AML was identified by flow cytometry with typical expression of monocytic markers, and M5 was identified according to French, American, and British category. We compared the outcomes of patients with different characteristics.

Results

The rate of complete remission (CR) and CR with incomplete recovery of blood counts

SUBMITTER: Jin D 

PROVIDER: S-EPMC11258555 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature